Dr. Sian Cooper's patients now walk out of the Royal Marsden NHS Foundation Trust in London after just two radiotherapy sessions spanning eight days—a radical compression of what has traditionally demanded weeks of daily hospital visits. The HERMES study, one of the first to randomly assign prostate cancer patients to either two or five radiotherapy doses, presents findings that could reshape treatment for thousands of men: using an MRI-guided radiotherapy machine for precision targeting, two larger doses delivered no additional side effects compared to the conventional five-session protocol.
For patients with localized prostate cancer, the implications ripple outward. Radiotherapy remains one of the primary curative treatments, yet the current standard of five sessions stretched over two weeks demands a relentless commitment to hospital appointments. Working parents, people living far from specialist centers, those juggling travel schedules—all face disruption that compounds the stress of a cancer diagnosis. Two sessions over eight days transforms that equation. The convenience matters not just personally but systemically: faster patient throughput means health systems can serve more people efficiently, and the financial savings accumulate across hospital workflows.
The HERMES team recruited 46 patients with prostate cancer. Twenty-four received the standard five doses over two weeks; 22 received the equivalent total dose compressed into two sessions over eight days. The treatment was delivered on a state-of-the-art machine combining MRI scanning with radiotherapy capability—technology that allows clinicians to visualize the prostate with exceptional precision while protecting surrounding healthy tissue from unnecessary radiation.
The safety profile proved reassuring. Around one in four patients in both groups experienced moderate urinary side effects such as increased frequency or urgency between six months and two years after treatment. Critically, neither group experienced severe urinary or bowel complications. The two-session group reported no bowel side effects at all. Two years post-treatment, patients in both cohorts reported minimal change in quality of life, with no meaningful difference in side effects between the condensed and standard schedules.
Professor Matthias Guckenberger, ESTRO President and a specialist at University Hospital Zurich who was not involved in the research, contextualizes the finding within radiotherapy's broader promise. "It is reassuring for patients to know that potential side effects are not affected by a more condensed treatment plan," he noted. For decades, the assumption held that spreading treatment over longer periods provided the most effective approach. This study suggests otherwise: delivering higher doses in fewer sessions proves both effective against cancer and gentle on quality of life.
The technology enabling this advance remains concentrated in specialist centers worldwide, but Guckenberger emphasized that availability is expanding rapidly. Results like these help guide how emerging centers deploy MRI-guided radiotherapy and suggest a pathway toward two-session treatment becoming a new standard of care.
What emerges is a portrait of medical progress rooted in patient reality. Fewer hospital visits mean more work days reclaimed, more family time preserved, fewer travel obstacles for rural patients. It means a diagnosis that once demanded weeks of disruption now requires eight days. For prostate cancer patients, that shift is not merely convenient—it is a fundamental reordering of what treatment looks like in their lives.